Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin for gastric cancer with peritoneal metastasis
KCT0005802Phase 2Not yet recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jan 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, capecitabine, oxaliplatin in gastric cancer (GC), sponsored by Hanmi Pharmaceutical. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
paclitaxelcapecitabineoxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0005802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005802.